Biotech firms are experiencing a fundraising boom in US equity markets, with a record $6.2 billion raised in January 2024 - the highest amount since February 2021. This increase follows a two-year downturn, boosted by positive market sentiments, anticipated Federal Reserve rate cuts, and a rise in M&A activities. The influx of funds primarily aids established companies, though IPOs are also on the rise. 

Despite some investor hesitancy towards early-stage companies, successful IPOs reflect increasing sector confidence, underpinned by strong clinical data and renewed interest from specialist investors.

For more, please find the original story source here.